Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . Lu ye Pharma 绿叶 制药 LUYE PHARMA GROUP LTD . 绿叶 制药 集团 有限公司 ( Incorporated in Bermuda with limited liability ) ( Stock Code : 02186 ) ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026 FINANCIAL HIGHLIGHTS Revenue decreased by RMB179.0 million or 5.6 % to RMB3,002.1 million , as compared to the six months ended 30 June 2025 . Gross profit decreased by RMB255.3 million or 11.8 % to RMB1,902.3 million , as compared to the six months ended 30 June 2025 , and gross profit margin was 63.4 % . Net profit increased by RMB23.4 million or 6.5 % to RMB380.8 million , as compared to the six months ended 30 June 2025 . Profit attributable to shareholders increased by RMB77.6 million or 24.8 % to RMB390.5 million , as compared to the six months ended 30 June 2025 . EBITDA increased by RMB47.0 million or 3.9 % to RMB1,251.2 million , as compared to the six months ended 30 June 2025 . Basic earnings per share was RMB9.78 cents compared to RMB8.32 cents for the six months ended 30 June 2025 . No interim dividend was proposed by the Board for the six months ended 30 June 2026 . − 1 −